Sugi Predict

Sugi Predict / Compounds / Asparagine

Asparagine

Asparagine

SCHEMBL2902137

CC(C)[C@H](N)C(N)=O.C[C@H](N)C(=O)O.NC(=O)C[C@H](N)C(=O)O.O=C(O)[C@@H]1[C@@H](c2ccc3ccccc3c2)CCN1C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 6/20 0.35
▸ TACR1 P25103 1/20 0.32
▸ FABP7 O15540 1/20 0.31
▸ FABP5 Q01469 1/20 0.31
▸ PIN1 Q13526 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asparagine SCHEMBL7855451 0.96 MC4R (0.36) MC4RTACR1FABP7FABP5PIN1
SCHEMBL2906513 0.84 FABP5 (0.42) FABP7FABP5
Asparagine SCHEMBL2902050 0.76 SLC1A3 (0.34) MC4R
SCHEMBL1675974 0.74 FABP5 (0.50) MC4RTACR1FABP7FABP5
SCHEMBL1675971 0.74 FABP5 (0.50) MC4RTACR1FABP7FABP5
Asparagine SCHEMBL2927424 0.71 SLC1A3 (0.32) —
SCHEMBL31524267 0.71 FABP5 (0.43) FABP7FABP5
SCHEMBL31582094 0.71 FABP5 (0.43) FABP7FABP5
SCHEMBL4040012 0.67 FABP5 (0.45) FABP7FABP5
Asparagine SCHEMBL2902140 0.67 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2239270-A2 Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2010-10-13 — — EP disclosed
EP-1845106-B1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-11 — — EP disclosed
EP-1845106-A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2007-10-17 — — EP disclosed
EP-1157040-B1 LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-22 — — EP disclosed
US-6365572-B1 FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-02 — — US disclosed
EP-1070727-A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction Aventis Pharma Deutschland GmbH (DE) 2001-01-24 — — EP disclosed